Organ Transplant Immunosuppressant Drugs Market: Emerging Market Trends, Size, Share and Growth Analysis

The global organ transplant immunosuppressant drugs market is fairly consolidated, with the top 5 vendors contributing over 90% of the market in 2014. Transparency Market Research (TMR) notes that these leading companies–Novartis AG, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Sanofi–are offering a robust and diverse product portfolio, including blockbuster drugs, to consolidate their market shares. They are updating their pipelines after the impending patient expiry of blockbuster drugs.
The increasing incidence rate of various life-threatening ailments has stimulated the demand for organ replacement therapies and transplants as the last line of treatment to treat organ failures or disabilities. This is a key driver fuelling the growth of the market. According to the TMR’s estimation, the global organ transplant immunosuppressant market was valued at US$5.1 bn in 2014. The market is anticipated to register a CAGR of -5.0% between 2015 and 2023 with the market’s valuation estimated to reach US$3.2 bn by 2023.
This 102 page report gives readers a comprehensive overview of the organ transplant immunosuppressant drugs market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html
Immunosuppressant Drugs for Successful Kidney Transplantation Propel Market Growth
Over the last couple of years, kidney transplantation has emerged as the preferred treatment method for end-stage kidney disorder, as the replacement proves to be more cost-effective than dialysis. The use of immunosuppressant drugs has been considered as a vital element for the long-term success of kidney transplants. According to findings by TMR, the segment occupied over 53.4% of the market in 2014 and is expected to lead the market through 2023. Rising incidence rate of kidney disorders is expected to fuel the growth of this segment. Furthermore, the rising incidence other of chronic ailments, which may need liver, heart, and lung transplants, mainly among geriatric population, is expected to spur the demand for organ transplant immunosuppressant drugs.
In addition, the emerging demand for bone marrow transplant has expedited the discovery of novel immunosuppressant drugs and therapies. Recent developments suggest that immunosuppression is found to offer promising line of treatment for the management of graft-versus-host diseases.
High Cost of Organ Replacement Surgeries may Act as Restraint
The high cost of organ transplant procedures, significant shortage of donors, and the considerable expenditure required for the care of patients post-transplantation are likely to restrain the growth of the market in some regions. Combined with them, the non-adherence of the immunosuppression therapies after transplantation owing to the lack of awareness among patients is another key restraining factor. Additionally, uncertainty of benefits of the use of immunosuppression for complex transplantation procedures, especially evident in case of liver transplantation, has impeded the market growth. In addition, the advent of stem cell therapies as a potential substitute for organ transplantation may restrict the growth of the global organ transplant immunosuppressant drugs market.
However, extensive clinical studies and R&D activities undertaken to develop and test novel immunosuppressant therapeutics is a key trend that will help minimize the cases of organ rejection for a number of transplantations, unlocking promising growth opportunities for the market players.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving organ transplant immunosuppressant drugs market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967
Robust Healthcare Infrastructure to Spur Demand for Organ Transplant Immunosuppressant Drugs in North America
Regionally, North America is a prominent market for organ transplant immunosuppressant drugs. The growth is driven by the increasing rate of successful organ replacement surgeries and substantial investments from the government and private players to develop a robust healthcare infrastructure.
Europe is another region exhibiting tremendous potential for growth in the organ transplant immunosuppressant drugs market. Continuous advancements in surgical procedures for organ transplantation and innovations in immunosuppressant drug discovery are the crucial factors propelling the market growth in the region.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Organ Transplant Immunosuppressant Drugs Market: Worldwide Market Shares, Strategies, and Forecasts 2015 to 2023

The global organ transplant immunosuppressant drugs market exhibits a highly consolidated vendor landscape. The top five companies held more than 90% of the market in 2014. These companies boast a strong and diverse product portfolio that has helped them attain a leading position in the market. Transparency Market Research (TMR) finds that in order to gain a stronger footprint, the leading companies are continuously engaged in the research and development of novel therapeutics.

“Despite the impending patient expiry of blockbuster drugs, the leading companies are looking to update their pipelines to ensure sustainable growth in the market,” said a lead TMR analyst. Besides this, the companies are also focusing on collaborations and mergers and acquisitions to strengthen their value chain.

This 102 page report gives readers a comprehensive overview of the organ transplant immunosuppressant drugs market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html

Rising Organ Replacement Therapies Boosts Sales of Immunosuppressant Drugs

The increasing incidence of life-threatening diseases has augmented the demand for organ replacements and transplants as last resorts of treatment in case of organ failure or disabilities. Due to this, the number of people registering for organ transplantation has significantly increased as well. The increase in geriatric population directly influences the demand for organ transplants since aged people are more vulnerable to kidney and heart diseases. The rising incidence of chronic ailments will therefore fuel demand for organ transplant immunosuppressant drugs.

High Cost of Organ Replacement Surgeries Poses Threat to Market

“Despite witnessing increasing demand, the high cost of organ transplant procedures limits the scope for the market’s expansion,” observed the TMR analyst. Non-adherence of patients to immunosuppressive medicines across developing regions is often related to their high cost and the patient’s inability to pay for the same. Furthermore, the high cost of post-transplantation care presents a significant barrier to the development of transplantation capacity in middle-income countries. The inadequate insurance coverage also limits the sales of organ transplant immunosuppressant drugs in these countries.

The development of immunosuppressant drugs help overcome conditions related to organ rejection. Significant advances have been made in the field of medicine and technology, yet a large section of global population is yet become aware about organ transplantation and donation. This has created a considerable shortage of donor organs, thus negatively impacting the sales of immunosuppressant drugs.

Besides this, the advent of stem cell therapies could eventually reduce the need for organ transplants. This also threatens the growth prospects of the organ transplant immunosuppressant drugs market.

Nevertheless, extensive studies are underway to develop and test novel immunosuppressant therapeutics to prevent organ rejection. Such research and development activities will create opportunities for the market to gain from in the forthcoming years.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving organ transplant immunosuppressant drugs market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967

According to TMR, the global organ transplant immunosuppressant drugs market stood at US$5.1 bn in 2014. Rising at a CAGR of -5.0%, the market is expected to reach US$3.2 bn by the end of 2023.

Based on the type of transplantation performed across the world each year, the demand for immunosuppressant drugs used in kidney transplantation was the highest in 2014. The segment held over 53.4% of the market’s revenue in the year. Regionally, North America dominated the global market with a share of 46.2% in 2014. The region is expected to continue to be a key contributor to the market through the report’s forecast period from 2015 to 2023.

This review is based on findings published by TMR, in a report, titled “Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Key Takeaways:

• Inadequate insurance coverage to limit sales of immunosuppressant drugs in developing countries.
• North America dominated the global immunosuppressant drugs market in 2014 with a share of 46.2%.
• Advent of stem cell therapy will contribute to declining CAGR of the market at -5.0% from 2014 to 2023.

Organ Transplant Immunosuppressant Drugs Market Outlook to 2015Latest Industry Forecast Report

According to a new market report published by Transparency Market Research “Organ Transplant Immunosuppressant Drugs Market: (By Drug Class: Calcineurin Inhibitors, Anti-proliferative Agents, mTOR Inhibitors, Antibodies, Steroids; By Transplant: Kidney, Bone Marrow, Liver, Heart, Lung, Others): Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2015 – 2023,” the global organ transplant immunosuppressant drugs market was valued at US$5.1 bn in 2014 and is expected to decline at a CAGR of – (5.0)% from 2015 to 2023, to reach an estimated value of US$3.2 bn in 2023.

Browse Full Report: http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html

Organ transplantation is a procedure wherein a healthy organ is transferred from a living or dead body into another individual’s body. It is the primary treatment option for end-stage organ failure. The process can also involve transplantation of more than one organ at a time. Immunosuppressant drugs are also known as anti-rejection drugs and prescribed after an organ transplant procedure. The objective of using immunosuppressant drugs is to lower the body’s ability to reject a transplanted organ. With increasing number of procedures of organ transplantation, the organ transplant immunosuppressant drugs market is anticipated to grow further. Additionally, rising health care expenditure, growing elderly population, and skilled expertise in performing the procedures are the other factors supporting the market growth. According to a report published by the World Health Organization (WHO) in 2013, approximately 118,127 solid organs were reported to be transplanted globally which was an increase of more than 2.5% over 2012. However, high cost of the procedure, inadequate insurance coverage, and lack of organ donors restricts the growth of the organ transplant immunosuppressant drugs market.

Geographically, the organ transplant immunosuppressant drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America held the largest share of the global organ transplant immunosuppressant drugs market in terms of revenue in 2014, followed by Europe. The dominance of these two regions was majorly due to more number of donors, high health care expenditure, and skilled expertise in performing the procedures. In North America, the U.S. accounted for major market share due to presence of leading manufacturers in the region and high awareness about organ transplant. North America is expected to maintain its position during the forecast period from 2015 to 2023.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967

Currently, Europe accounts for the second largest share of the global organ transplant immunosuppressant drugs market owing to increasing geriatric population coupled with rising number of people diagnosed with end stage organ failure. The German Organ Transplantation Foundation (DSO) reported in 2012 that within every one million people living in Spain, 32 have donated an organ as of 2010. Germany, Spain and France witnessed highest number of organ transplants in 2013. Hence, growth in Europe would emerge from Germany, Poland, the Netherlands and other countries as organ transplant immunosuppressant drugs become more widespread in these countries.

Allergan plc, AbbVie, Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Janssen Pharmaceuticals, Astellas Pharma, Inc, Veloxis Pharmaceuticals A/S, Novartis AG, and Sanofi S.A. are the major players operating in the organ transplant immunosuppressant drugs market globally. Novartis AG was identified as the leading player in the global organ transplant immunosuppressant drugs market in 2014, accounting for a revenue share of more than 32.4%, followed by Astellas Pharma.